RYTM

NASDAQ 已收盘

Rhythm Pharmaceuticals

116.80 USD
▼-2.24-1.88%
盘后 117.00 +0.17%
2026-11-19
市值
$7.87B
市盈率
—
EPS
-2.91
股息率
—
52 周区间
74.50 – 122.20
成交量
1.11M
Beta
2.13
目标价
139.76
52W 低 74.5052W 高 122.20
价格走势

公司简介

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic...

关联新闻